FDA Approves LYTENAVA (BLA761320) from Outlook Therapeutics
The FDA has approved LYTENAVA (BLA761320), a new formulation of Bevacizumab by Outlook Therapeutics.
Asset / Drug
Drug and asset intelligence for Bevacizumab with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.